Skip to main content

Table 2 Percentage of low and high infliximab serum trough levels and presence of anti-infliximab antibodies in patients with low and high DAS28 at the first study visit

From: Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

  No infliximab serum trough level Low* infliximab trough levels Intermediate infliximab trough levels High** infliximab trough levels Anti-infliximab antibodies Total
DAS28 % (95%CI) % (95%CI) % (95%CI) % (95%CI) % (95%CI) No patients
<2.6 13 (2–23) 23 (10–35) 48 (32–63) 18 (6–29) 13 (2–23) 40
≤3.2 13 (4–20) 18 (9–28) 55 (43–67) 14 (5–22) 11 (3–19) 65
>3.2 29 (19–39) 18 (10–27) 32 (22–42) 21 (12–30) 29 (19–39) 82
  1. * Low serum trough levels are defined as <1.0 mg/L.
  2. ** High serum trough levels are defined as >5.0 mg/L.
\